Cargando…

Trial participants' rights after authorisation of COVID-19 vaccines

Detalles Bibliográficos
Autores principales:	Dal-Ré, Rafael, Orenstein, Walter, Caplan, Arthur L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816575/ https://www.ncbi.nlm.nih.gov/pubmed/33476582 http://dx.doi.org/10.1016/S2213-2600(21)00044-8

Ejemplares similares

Current COVID-19 vaccine trials in high-income countries: are placebo-controlled trials ethical?
por: Dal-Ré, Rafael, et al.
Publicado: (2021)

The approach to informed consent in acute care research
por: Dal-Ré, Rafael, et al.
Publicado: (2022)

Participants’ informed consent in adaptive, platform drug trials in hospitalized COVID-19 patients: Not all approaches are ethically acceptable
por: Dal-Ré, Rafael, et al.
Publicado: (2022)

Placebo-controlled trials with COVID-19 vaccines: participants first
por: Dal-Ré, Rafael
Publicado: (2021)

COVID-19 drug research and the cohort multiple randomised controlled trial design
por: Dal-Ré, Rafael
Publicado: (2022)

COVID-19 vaccine research and the trouble with clinical equipoise
por: Friesen, Phoebe, et al.
Publicado: (2021)

Stigma, vaccination, and moral accountability
por: Caplan, Arthur L
Publicado: (2022)

FDA limits authorised use of Janssen COVID-19 vaccine
Publicado: (2022)

US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine
por: Dal-Ré, Rafael
Publicado: (2021)

Placebo control group in COVID-19 vaccine trials: context and timing matters
por: Dal-Ré, Rafael
Publicado: (2021)

Emergency use authorisation for COVID-19 vaccines: lessons from Ebola
por: Smith, Maxwell J, et al.
Publicado: (2020)

Caution Required in the Use of Administrative Data and General Laboratory Submissions for Influenza Vaccine Effectiveness Estimation
por: Skowronski, Danuta M, et al.
Publicado: (2019)

COVID-19 ARDS: getting ventilation right – Authors' reply
por: Barbaro, Ryan P, et al.
Publicado: (2022)

The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines
por: Cavaleri, Marco, et al.
Publicado: (2021)

COVID-19 ARDS: getting ventilation right
por: Pérez-Fernández, Xosé L, et al.
Publicado: (2022)

GANIL authorised
Publicado: (1975)

Sex-disaggregated data in COVID-19 vaccine trials
por: Vijayasingham, Lavanya, et al.
Publicado: (2021)

Editors’ and authors’ individual conflicts of interest disclosure and journal transparency. A cross-sectional study of high-impact medical specialty journals
por: Dal-Ré, Rafael, et al.
Publicado: (2019)

Myocarditis after Covid-19 mRNA Vaccination
por: Verma, Amanda K., et al.
Publicado: (2021)

Pyoderma gangrenosum after COVID-19 infection and vaccination
por: Zou, Henry, et al.
Publicado: (2022)

Who should be vaccinated against COVID-19 first?()
por: Dal-Ré, Rafael, et al.
Publicado: (2021)

Erythema nodosum, after Medigen vaccination against COVID-19?
por: Hsu, Hui-Te, et al.
Publicado: (2022)

Reactivation of IgA vasculitis after COVID-19 vaccination
por: Obeid, Michel, et al.
Publicado: (2021)

Guillain-Barré syndrome after vaccination against COVID-19
por: Chun, June Young, et al.
Publicado: (2022)

Early Reversal of Right Ventricular Dysfunction after Venovenous Extracorporeal Membrane Oxygenation in Patients with COVID-19 Pneumonia
por: Levy, David, et al.
Publicado: (2022)

Clinical course of 12 patients on a Covid-19 dementia isolation ward
por: Kerslake, Richard, et al.
Publicado: (2020)

Is IL-6 the Right Target in COVID-19 Severe Pneumonia?
por: Blot, Mathieu, et al.
Publicado: (2021)

COVID-19 May Be Exacerbated by Right-to-Left Interatrial Shunt
por: Rajendram, Rajkumar, et al.
Publicado: (2021)

Response to case report on myocarditis and pericarditis after COVID‐19 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients
por: Carr, Edward J, et al.
Publicado: (2021)

Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients
por: Carr, Edward J, et al.
Publicado: (2022)

Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs
por: Sisa, Ivan, et al.
Publicado: (2021)

Regulatory approval of COVID-19 vaccine for restricted use in clinical trial mode
por: Mohapatra, Prasanta Raghab, et al.
Publicado: (2021)

Cerebral venous thrombosis after COVID-19 vaccines: Do we know the mechanism?
por: de Gregorio, Cesare, et al.
Publicado: (2022)

“Let me choose my COVID-19 vaccine”
por: Dal-Ré, Rafael, et al.
Publicado: (2021)

Adverse event reporting and Bell's palsy risk after COVID-19 vaccination
por: Chang, Kwok-Chiu, et al.
Publicado: (2021)

Adverse event reporting and Bell's palsy risk after COVID-19 vaccination
por: Khouri, Charles, et al.
Publicado: (2021)

Evaluation of Acute Adverse Events after Covid-19 Vaccination during Pregnancy
por: DeSilva, Malini, et al.
Publicado: (2022)

Systemic lupus erythematosus with acrocyanosis after AstraZeneca COVID‐19 vaccination
por: Wang, Huei‐Jing, et al.
Publicado: (2022)

Severe bullous drug reaction after COVID‐19 mRNA vaccination
por: Irmer, Marie Luise, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6t8e6n26pr3293mp33h06ijgba